Developing a new vaccine approach to enhance HIV antibody responses
Official title: Scientific Project One
Funded at Fred Hutchinson Cancer Center · NIH-11238213 · Data updated 2026-11-12
This study is testing new types of vaccines designed to help your immune system fight HIV better, and it may involve patients trying out these innovative vaccines to see how they work compared to the usual ones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 30, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $525,472 |
| NIH project number | 5U19AI174242-03 |
| Project ID | NIH-11238213 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals who are at risk for HIV or those who are interested in contributing to HIV vaccine development.
✕Less likely to help
Patients who are already HIV-positive or those who have a history of severe allergic reactions to vaccine components may not benefit from this research.
What this research studies
This research focuses on creating innovative vaccines that target specific immune cells to improve the body's response to HIV. It involves using a recombinant HIV-1 protein to activate naïve B cells and enhance the production of broadly neutralizing antibodies. The study will also explore alternative vaccination methods, such as self-amplifying RNA vaccines, which may offer advantages in terms of production and effectiveness. Patients may be involved in trials to assess how well these new vaccines work compared to traditional methods.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against HIV.
How similar studies have gone: Other research has shown promise in using RNA vaccine platforms for various diseases, indicating potential success for this novel approach in HIV.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Stamatatos, Leonidas — Fred Hutchinson Cancer Center
- Study coordinator: Stamatatos, Leonidas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.